Amy B Heimberger
Overview
Explore the profile of Amy B Heimberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
237
Citations
12364
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Najem H, Pacheco S, Turunen J, Tripathi S, Steffens A, McCortney K, et al.
bioRxiv
. 2025 Mar;
PMID: 40027731
Sequential multiplex methodologies such as Akoya CODEX, Miltenyi MACSima, Rarecyte Orion, and others require modification of the antibodies by conjugation to an oligo or a specific fluorophore which means the...
2.
Pedder J, Sonabend A, Cearns M, Michael B, Zakaria R, Heimberger A, et al.
Lancet Neurol
. 2025 Jan;
24(3):246-260.
PMID: 39862873
The blood-brain barrier is a physiological barrier that can prevent both small and complex drugs from reaching the brain to exert a pharmacological effect. For treatment of neurological diseases, drug...
3.
Baskaran A, Kozel O, Venkatesh O, Wainwright D, Sonabend A, Heimberger A, et al.
Cancers (Basel)
. 2025 Jan;
16(24).
PMID: 39766048
Purpose: A glioblastoma (GBM) is a primary brain tumor with significant unmet therapeutic needs. Immune checkpoint inhibitors (ICIs) have marked therapeutic benefits in many different cancers but have yet to...
4.
Zannikou M, Zannikou M, Duffy J, Procissi D, Najem H, Levine R, et al.
bioRxiv
. 2025 Jan;
PMID: 39763755
Background: Bispecific T cell-engagers (BTEs) are engineered antibodies that redirect T cells to target antigen-expressing tumors. BTEs targeting tumor-specific antigens such as interleukin 13 receptor alpha 2 (IL13Rα2) and EGFRvIII...
5.
Du R, Zhang J, Lukas R, Tripathi S, Ahrendsen J, Curran M, et al.
Neuro Oncol
. 2024 Oct;
27(1):33-49.
PMID: 39427326
The field of immunology has traditionally focused on immune checkpoint modulation of adaptive immune cells. However, many malignancies such as glioblastoma are mostly devoid of T cells and rather are...
6.
Liu Y, Wu J, Najem H, Lin Y, Pang L, Khan F, et al.
J Clin Invest
. 2024 Oct;
134(22).
PMID: 39352749
Tumor-associated macrophages and microglia (TAMs) are critical for tumor progression and therapy resistance in glioblastoma (GBM), a type of incurable brain cancer. We previously identified lysyl oxidase (LOX) and olfactomedin...
7.
8.
Wang S, Castro B, Katz J, Arrieta V, Najem H, Vazquez-Cervantes G, et al.
J Clin Invest
. 2024 Aug;
134(20).
PMID: 39207859
Glioblastoma (GBM) is a highly aggressive and malignant brain tumor with limited therapeutic options and a poor prognosis. Despite current treatments, the invasive nature of GBM often leads to recurrence....
9.
Tripathi S, Najem H, Dussold C, Pacheco S, Du R, Sooreshjani M, et al.
J Clin Invest
. 2024 Aug;
134(19).
PMID: 39137048
Despite being the leading cause of cancer-related childhood mortality, pediatric gliomas have been relatively understudied, and the repurposing of immunotherapies has not been successful. Whole-transcriptome sequencing, single-cell sequencing, and sequential...
10.
Pang L, Zhou F, Liu Y, Ali H, Khan F, Heimberger A, et al.
J Clin Invest
. 2024 Aug;
134(12).
PMID: 39133578
Although cancer has long been considered a genetic disease, increasing evidence shows that epigenetic aberrations play a crucial role in affecting tumor biology and therapeutic response. The dysregulated epigenome in...